BioCentury | Apr 19, 2004
Strategy

Making the 'make' decision

Drug discovery and development is like the portion of an iceberg that is above water: visible and dramatic. Manufacturing is like the portion that is under water: out of sight and often out of mind....
BC Week In Review | Apr 15, 2002
Company News

Fresenius AG, Genzyme Transgenics sales and marketing update

Fresenius exercised its option for additional rights to market GZMO's recombinant human serum albumin (rhSA) in Japan, adding to it marketing rights in the rest of Asia, Europe and North America. Fresenius paid GZTC $1.2...
BC Week In Review | Jan 14, 2002
Company News

Panacos board of directors update

Panacos Pharmaceuticals Inc., Gaithersburg, Md.   Business: Infectious diseases   Appointed: Sandra Lehrman, former president and CEO of Genzyme Transgenics Corp.  ...
BC Week In Review | Dec 24, 2001
Company News

Genzyme Transgenics other research news

Scientists reported in the Proceedings of the National Academy of Sciences that vaccination with a non-glycosylated form of MSP1-42 purified from the milk of transgenic mice protected 4 of 5 monkeys from a lethal challenge...
BioCentury | Oct 1, 2001
Finance

Enterprising values?

Enterprising values? Company 9/21mkt cap 6/30 cash Market cap as multiple of cash Genset (GENXY; NM:Genset) $17.5M $36.96M 0.5 Matrix (MATX) $19.8M $41.3M 0.5 Genomica (GNOM) $58.0M $115.5M 0.5 Diacrin (DCRN) $28.7M $52.3M 0.5 Maxim...
BioCentury | Aug 20, 2001
Finance

Ebb & Flow

Europe may be in danger of following the U.S. into a recession, but investors are still pouring money into venture funds. Two new funds are looking to add more than half a billion dollars to...
BioCentury | Aug 13, 2001
Finance

Ebb & Flow

Genzyme (GENZ) moved to consolidate its grip in the enzyme replacement space, but wasn't instantly rewarded for its plans to acquire protein engineering play Novazyme for $137.5 million in stock. After pushing GENZ up $0.26...
BC Week In Review | Jul 30, 2001
Company News

Genzyme Transgenics, Fresenius AG, ProMetic BioSciences Inc. sales and marketing update

Fresenius exercised its option to expand its marketing rights to recombinant human serum albumin made by GZTR and PLI to include North America and Asia. Under a 1997 agreement, Fresenius already had marketing rights in...
BC Week In Review | Jul 23, 2001
Company News

Genzyme Transgenics, Fresenius AG deal

Fresenius exercised an option under a 1997 agreement to obtain for $3.8 million rights to market GZTC's recombinant human serum albumin (rhSA) in North America and Asia, except Japan (see BioCentury, March 17, 1997). Fresenius,...
BC Week In Review | Jul 23, 2001
Company News

Genzyme Transgenics management update

Genzyme Transgenics Corp. (GZTC), Framingham, Mass.   Business: Biomanufacturing, Cardiovascular   Hired: Geoffrey Cox, a director, as chairman and CEO, formerly chairman and CEO of Aronex Pharmaceuticals Inc. ; former chairman James Geraghty will remain...
Items per page:
1 - 10 of 155
BioCentury | Apr 19, 2004
Strategy

Making the 'make' decision

Drug discovery and development is like the portion of an iceberg that is above water: visible and dramatic. Manufacturing is like the portion that is under water: out of sight and often out of mind....
BC Week In Review | Apr 15, 2002
Company News

Fresenius AG, Genzyme Transgenics sales and marketing update

Fresenius exercised its option for additional rights to market GZMO's recombinant human serum albumin (rhSA) in Japan, adding to it marketing rights in the rest of Asia, Europe and North America. Fresenius paid GZTC $1.2...
BC Week In Review | Jan 14, 2002
Company News

Panacos board of directors update

Panacos Pharmaceuticals Inc., Gaithersburg, Md.   Business: Infectious diseases   Appointed: Sandra Lehrman, former president and CEO of Genzyme Transgenics Corp.  ...
BC Week In Review | Dec 24, 2001
Company News

Genzyme Transgenics other research news

Scientists reported in the Proceedings of the National Academy of Sciences that vaccination with a non-glycosylated form of MSP1-42 purified from the milk of transgenic mice protected 4 of 5 monkeys from a lethal challenge...
BioCentury | Oct 1, 2001
Finance

Enterprising values?

Enterprising values? Company 9/21mkt cap 6/30 cash Market cap as multiple of cash Genset (GENXY; NM:Genset) $17.5M $36.96M 0.5 Matrix (MATX) $19.8M $41.3M 0.5 Genomica (GNOM) $58.0M $115.5M 0.5 Diacrin (DCRN) $28.7M $52.3M 0.5 Maxim...
BioCentury | Aug 20, 2001
Finance

Ebb & Flow

Europe may be in danger of following the U.S. into a recession, but investors are still pouring money into venture funds. Two new funds are looking to add more than half a billion dollars to...
BioCentury | Aug 13, 2001
Finance

Ebb & Flow

Genzyme (GENZ) moved to consolidate its grip in the enzyme replacement space, but wasn't instantly rewarded for its plans to acquire protein engineering play Novazyme for $137.5 million in stock. After pushing GENZ up $0.26...
BC Week In Review | Jul 30, 2001
Company News

Genzyme Transgenics, Fresenius AG, ProMetic BioSciences Inc. sales and marketing update

Fresenius exercised its option to expand its marketing rights to recombinant human serum albumin made by GZTR and PLI to include North America and Asia. Under a 1997 agreement, Fresenius already had marketing rights in...
BC Week In Review | Jul 23, 2001
Company News

Genzyme Transgenics, Fresenius AG deal

Fresenius exercised an option under a 1997 agreement to obtain for $3.8 million rights to market GZTC's recombinant human serum albumin (rhSA) in North America and Asia, except Japan (see BioCentury, March 17, 1997). Fresenius,...
BC Week In Review | Jul 23, 2001
Company News

Genzyme Transgenics management update

Genzyme Transgenics Corp. (GZTC), Framingham, Mass.   Business: Biomanufacturing, Cardiovascular   Hired: Geoffrey Cox, a director, as chairman and CEO, formerly chairman and CEO of Aronex Pharmaceuticals Inc. ; former chairman James Geraghty will remain...
Items per page:
1 - 10 of 155